Muvalaplin
LY3473329First oral Lp(a)-lowering drug. ACCLAIM-Lp(a) Phase 3 enrolling 10,450 patients with elevated Lp(a) + ASCVD.
Target: LPA oral small-molecule disrupting apo(a)/apoB binding Eli Lilly and Company Cardiometabolic
When will we know if it works?
Stale est.A positive readout makes LPA a validated target for the first time. Hover the badge above for what the confidence level means.
1
Phase 3 trials
1 active · 0 completed
1
Total trials
P2: 0 · P1: 0
10,450
Max trial size
across 2 indications
1
Sponsors at target
incl. 3 other assets
What does it do?
LPA — Apolipoprotein(a)
Modality: oral small-molecule disrupting apo(a)/apoB binding
Program: ACCLAIM-Lp(a)
The 1 Phase 3 trial
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT07157774 | Elevated Lp(a); Atherosclerotic Cardiovascular Disease (ASCVD) | 10,450 | RECRUITING | 2025-09-02 | 2031-03 | Stale est. |
What's the case for and against?
✓ What's working in its favor
- Phase 2: ~85% reduction in Lp(a) levels
- First oral therapy for Lp(a) — convenience advantage over injectable ASOs/siRNAs
Who else is racing? — 3 other assets at LPA
| Asset | Sponsor | Status |
|---|---|---|
| Pelacarsen | Novartis | P3 HORIZON |
| Olpasiran | Amgen | P3 OCEAN(a) |
| Zerlasiran | Silence Therapeutics | P2 |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.